T. Murphy

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

M. Grever, J. Byrd, I. Flinn, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

J. Byrd, M. Sipe, C. White, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.

M. Grever, J. Byrd, I. Flinn, 2000, Blood.

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells

M. Grever, J. Byrd, C. Plass, 2003, Leukemia.

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.

M. Grever, J. Byrd, John Calvin Reed, 2003, Blood.